NEWS
November 03, 2022
ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous Nephropathy
August 24, 2022
ValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors
March 31, 2022
ValenzaBio Announces FDA Clearance of Investigational New Drug Application for VB421, an Anti-IGF-1R Monoclonal Antibody for the Treatment of Thyroid Eye Disease
February 15, 2022
February 15, 2022
ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody
July 27, 2021
ValenzaBio Partners With ProBioGen to Maximize Cell Line Productivity and Licenses GlymaxX®
July 27, 2021
ValenzaBio Partners With ProBioGen to Maximize Cell Line Productivity and Licenses GlymaxX®
June 18, 2021
June 18, 2021
Lonza and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, an Anti-IGF-1R Antibody for Autoimmune Diseases
May 27, 2021
ValenzaBio Appoints Biotech Veteran Gregory Keenan, M.D., as Chief Medical Officer
May 26, 2021
ValenzaBio Selects Ready by ArcheMedX to Expedite Biomarker Study
April 08, 2021
April 08, 2021
ValenzaBio Advances Pipeline of Antibody Therapeutics Toward Clinical Development for Autoimmune and Inflammatory Diseases